Treatment of depression in cardiovascular disease

Depression and Anxiety

Volumn 30, Issue 4, 2013, Pages 328-341

  Mavrides, Nicole ^a   Nemeroff, Charles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressants; cardiovascular disease; clinical trials; depression; treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; CITALOPRAM; DOXEPIN; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; INTERLEUKIN 1; INTERLEUKIN 6; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THROMBOCYTE FACTOR 4; TRIMIPRAMINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ARTICLE; BRADYCARDIA; BRAIN SCINTIANGIOGRAPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; GROUP THERAPY; HEART BLOCK; HEART FAILURE; HEART RATE VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTERPERSONAL THERAPY; ISCHEMIC HEART DISEASE; LIFESTYLE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PSYCHODYNAMICS; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; TACHYCARDIA; THROMBOCYTE; TRANSCRANIAL MAGNETIC STIMULATION; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VAGUS NERVE STIMULATION;

ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 84876148086     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22051     Document Type: Article

References (62)

1. Halaris A,. Comorbidity between depression and cardiovascular disease. Int Angiol 2009; 28: 92-99.
2. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctot KL,. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry 2010; 55 (2): 91-99.
3. Celano CM, Huffman JC,. Depression and cardiac disease. A Review. Cardiol Rev 2011; 19 (3): 130-142.
4. Maltzberg B,. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93: 1231-1238.
5. Nemeroff CB, Goldschmidt-Clermont PJ,. Heartache and heartbreak-the link between depression and cardiovascular disease. Nat Rev Cardiol 2012;Sep 9 (9): 526-539.
6. Bucknall C, Brooks D, Curry PV, Bridges PK, Bouras N, Ankier SI,. Mianserin and trazodone for cardiac patients with depression. Eur J Clin Pharmacol 1988; 33 (6): 565-569.
7. Scherrer JF, Garfield LD, Lustman PJ, et al. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med 2011; 124: 318-324.
8. Scherrer JF, Chrusciel T, Garfield LD, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry 2012; 200: 137-142.
9. Sowden GL, Huffman JC,. The impact of mental illness on cardiac outcomes: a review for the cardiologist. Int J Cardiol 2009; 132: 30-37.
10. Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D,. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analysis of safety and efficacy. Br J Psychiatry 2011; 198: 179-188.
11. Lesperance F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease. The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial. J Am Med Assoc 2007; 297: 367-379.
12. Alvarez W, Pickworth KK,. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy. 2003; 23 (6): 754-771.
13. McIntyre RS, Schaffer A, Beaulieu S,. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions. Ann Clin Psychiatry 2012; 24 (1): 1-3.
14. Cowles MK, Musselman DL, McDonald W, Nemeroff CB,. Effects of mood and anxiety disorders on the cardiovascular system. In:, Fuster V, Walsh R, Harrington R, editors. Hurst's the Heart, 13th edition, Chapter 96. New York: McGraw-Hill Publishers; 2010: 2128-2145.
15. Iosifescu DV, Clementi-Craven N, Fraguas R, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med 2005; 67: 703-706.
16. Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the women's health initiative study. Arch Intern Med 2009; 169 (22): 2128-2139.
17. Taylor CB, Conrad A, Wilhelm FH, et al. Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk ? J Psychiatr Res 2009; 43: 1246-1252.
18. Frasure-Smith N, Lesperance F, Talajic M,. Depression following myocardial infarction. Impact on 6 month survival. J Am Med Assoc 1993; 270: 1819-1825.
19. Pozuelo L, Zhang J, Franco K, Tesar G, Penn M, Jiang W,. Depression and heart disease: what do we know, and where are we headed? Cleve Clin J Med 2009; 76 (1): 59-70.
20. Ruo B, et al. Depressive symptoms and health related quality of life: the Heart and Soul Study. J Am Med Assoc 2003; 290: 215-221.
21. Gehi A, Haas D, Pipkin S, Whooley MA,. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005; 165 (21): 2508-2513.
22. Blumenthal JA,. New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. Cleve Clin J Med 2011; 78: S35-S43.
23. Hamer M, Batty GD, Seldenrijk A, Kivimaki M,. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Study. Eur Heart J 2010; 32 (4): 737-442.
24. Baumeister H, Hutter N, Bengel K,. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011; 9: CD008012.
25. Van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007; 190: 460-466.
26. Hoc J,. The clinical efficacy and side-effects of mianserin and nortriptyline in depressed outpatients: a double-blind randomized trial. Curr Med Res Opin 1982; 8 (4): 107-115.
27. Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL,. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982; 306: 954-959.
28. Kiev A, Masco HL, Wenger TL, Johnston JA, Batey SR, Holloman LC,. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry 1994; 6 (2): 107-115.
29. Roose SP, Glassman AH, Giardina EV, Johnson LL, Resovsky K, Le Winter M,. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol 1987; 7: 247-251.
30. Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntylre RS,. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry 2012; 24 (1): 82-90.
31. Van den Brink RHS, Van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial. Am Heart J 2002; 144 (2): 219-225.
32. Raskind M, Veith R, Barnes R, Gumbrecht G,. Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. Am J Psychiatry 1982; 139: 1114-1117.
33. Glassman AH, Bigger JT,. Depression and Cardiovascular Disease: the safety of antidepressant drugs and their ability to improve mood and reduce medical morbidity. In:, Mario Maj, Norman Sartorius, editors, Depression and Heart Disease. Chapter 5. New York: Wiley and Sons; 2011: 85-102.
34. Glassman AH, Johnson LI, Giardina EV,. The use of imipramine in depressed patients with congestive heart failure. J Am Med Assoc 1983; 250: 1997-2001.
35. Roose SP, Glassman AH, Giardina EV,. Nortriptyline in depressed patients with left ventricular impairment. J Am Med Assoc 1986; 256: 3253-3257.
36. Roose SP, Glassman AH,. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmias suppression trials (CAST) studies. J Clin Psychiatry 1994; 55 (Suppl A): 83-87.
37. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. J Am Med Assoc 1998; 279 (4): 287-291.
38. Dietch JT, Fine M,. The effect of nortriptyline in elderly patients with cardiac conduction disease. J Clin Psychiatry 1987; 44: 273-275.
39. Cohen BE, Panguluri P, Na B, Whooley MA,. Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: findings from the Heart and Soul Study. Psychiatry Res 2010; 175: 133-137.
40. Cohen JB, Wilcox CS, Goodman L,. Antidepressant efficacy and safety of trimipramine in patients with mild heart disease. Clin Theory 1993; 15: 114-126.
41. Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry 1999; 156 (7); 1024-1028.
42. Yeragani VK, Roose S, Mallavarapu M, Radhakrishna RK, Pesce V,. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology 2002; 46 (3): 125-135.
43. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EV, Bigger JT,. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155: 660-665.
44. Shapiro PA, Lesperance F, Frasure-Smith N,. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (SAHDAT trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J 1999; 37: 1100-1106.
45. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. J Am Med Assoc 2002; 288 (6): 401-709.
46. Strik JJ, Honig A, Lousberg R,. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind placebo-controlled trial. Psychosom Med 2000; 62: 783-789.
47. Habra ME, Baker B, Frasure-Smith N, et al. First episode of major depressive disorder and vascular factors in coronary artery disease. Baseline characteristics and response to antidepressant treatment in the CREATE trial. J Psychosom Res 2010; 69 (2): 133-141.
48. Bekke-Hansern S, Trockel M, Burg MM, Taylor CB,. Depressive symptom dimensions and cardiac prognosis following myocardial infarction: results from the ENRICHD clinical trial. Psychol Med 2012; 42: 51-60.
49. Carney RM, et al. Enhancing recovery in coronary heart disease (ENRICHD) study interventions: rationale and design. Psychosom Med 2001; 63: 747-755.
50. Honig A, et al. Treatment of post-myocardial infacrtion depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007; 69: 606-613.
51. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure. Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial. J Am Coll Cardiol 2010; 56 (9): 692-699.
52. Hansen BH, et al. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). J Psychosom Res 2012; 72: 11-16.
53. Santangelo A, Testai M, Barbagallo P, et al. Use of specific serotonin reuptake inhibitors (SSRIs) (sertraline or citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly. Evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Arch Gerontol Geriatr 2009; 48: 350-352.
54. Gottlieb SS, Kop WJ, Thomas SA, et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. Am Heart J 2007; 153: 868-873.
55. Paslakis G, Kopf D, Westphal S, et al. Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression. J Psychopharmacol 2010.
56. Weeke P, Jensen A, Folke F, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 2012; 92: 72-79.
57. Davidson KW, Rieckmann N, Clemow L, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms. Coronary Psychosocial Evaluation Studies Randomized Controlled Trial. Arch Intern Med 2010; 120 (7): 600-608.
58. Whang W, Shimbo D, Kronish IM, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]. Am J Cardiol 2010; 106 (8): 1104-1107.
59. Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery. Arch Gen Psychiatry 2009; 66 (4): 387-396.
60. Rollman BL, Herbeck BB,. The Bypassing the Blues Trial: collaborative care for post-CABG depression and implications for future research. Cleve Clin J Med 2011; 78 (Suppl 1): S4-S12.
61. Milani RV, Lavie CJ,. Impact of cardiac rehabilitation on depression and its associated mortality. Am J Med 2007; 120: 799-806.
62. O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, survival in patients with heart failure. Arch Intern Med 2008; 168 (2): 2232-2237.